Cargando…

Next Generation Antiobesity Medications: Setmelanotide, Semaglutide, Tirzepatide and Bimagrumab: What do They Mean for Clinical Practice?

There is a new generation of antiobesity drugs in development or just arriving on the scene. First, setmelanotide has been approved for three of the ultrarare genetic conditions that cause obesity–pro-opiomelanocortin deficiency, proprotein convertase subtilisin and kexin type 1 (an important enzyme...

Descripción completa

Detalles Bibliográficos
Autor principal:	Ryan, Donna H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Society for the Study of Obesity 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8526285/ https://www.ncbi.nlm.nih.gov/pubmed/34518444 http://dx.doi.org/10.7570/jomes21033

Ejemplares similares

Semaglutide and Tirzepatide reduce alcohol consumption in individuals with obesity
por: Quddos, Fatima, et al.
Publicado: (2023)

The Upcoming Weekly Tides (Semaglutide vs. Tirzepatide) against Obesity: STEP or SURPASS?
por: Jung, Han Na, et al.
Publicado: (2022)

Effect of bimagrumab on thigh muscle volume and composition in men with casting‐induced atrophy
por: Rooks, Daniel S., et al.
Publicado: (2017)

OR28-4 Efficacy and Safety of Tirzepatide Versus Semaglutide in a Hispanic or Latino Population: A Prespecified Subgroup Analysis of SURPASS-2
por: Benneyworth, Brian D, et al.
Publicado: (2022)

Safety and pharmacokinetics of bimagrumab in healthy older and obese adults with body composition changes in the older cohort
por: Rooks, Daniel, et al.
Publicado: (2020)

Efficacy of tirzepatide 5, 10 and 15 mg versus semaglutide 2 mg in patients with type 2 diabetes: An adjusted indirect treatment comparison
por: Vadher, Karan, et al.
Publicado: (2022)

Tirzepatide: A Systematic Update
por: Forzano, Imma, et al.
Publicado: (2022)

Adverse Events Related to Tirzepatide
por: Mishra, Rahul, et al.
Publicado: (2023)

Tirzepatide for type 2 diabetes
por: Anderson, Sarah L, et al.
Publicado: (2023)

Cost per Patient Achieving Treatment Targets and Number Needed to Treat with Tirzepatide Versus Semaglutide 1 mg in Patients with Type 2 Diabetes in the United States
por: Mody, Reema R., et al.
Publicado: (2023)

What is the BDA doing to support the next generation of dentists?
por: Westgarth, David
Publicado: (2020)

Bimagrumab vs Optimized Standard of Care for Treatment of Sarcopenia in Community-Dwelling Older Adults: A Randomized Clinical Trial
por: Rooks, Daniel, et al.
Publicado: (2020)

RF28 | PSUN198 The Dramatic Fat Mass Loss Caused by Bimagrumab is Similar in Diabetic and Non-diabetic Patients.
por: Klickstein, Lloyd, et al.
Publicado: (2022)

Advent of tirzepatide: boon for diabetic and obese?
por: Bhusal, Amrit
Publicado: (2023)

Tirzepatide and prevention of chronic kidney disease
por: Bosch, Catalina, et al.
Publicado: (2022)

Tirzepatide-Induced Injection Site Reaction
por: Mizumoto, Junki
Publicado: (2023)

ODP606 Long-term Efficacy of Setmelanotide in Patients With Bardet-Biedl Syndrome
por: Argente, Jesús, et al.
Publicado: (2022)

Setmelanotide: a promising advancement for pediatric patients with rare forms of genetic obesity
por: Trapp, Christine M., et al.
Publicado: (2023)

The Societal Value of Broader Access to Antiobesity Medications
por: Kabiri, Mina, et al.
Publicado: (2019)

The next‐generation K‐means algorithm
por: Demidenko, Eugene
Publicado: (2018)

Tirzepatide—Friend or Foe in Diabetic Cancer Patients?
por: Samuel, Samson Mathews, et al.
Publicado: (2022)

Effect of setmelanotide, a melanocortin‐4 receptor agonist, on obesity in Bardet‐Biedl syndrome
por: Haws, Robert, et al.
Publicado: (2020)

Natural History of Obesity Due to POMC, PCSK1, and LEPR Deficiency and the Impact of Setmelanotide
por: Wabitsch, Martin, et al.
Publicado: (2022)

ODP607 Long-term Efficacy of Setmelanotide in Patients With POMC or LEPR Deficiency Obesity
por: Clément, Karine, et al.
Publicado: (2022)

FRI082 Impact Of Setmelanotide On Metabolic Parameters And Vital Signs In Patients With Hypothalamic Obesity
por: Jennifer Abuzzahab, M, et al.
Publicado: (2023)

Designing a Dual GLP-1R/GIPR Agonist from Tirzepatide: Comparing Residues Between Tirzepatide, GLP-1, and GIP
por: Wang, Lijing
Publicado: (2022)

Plants' Metabolites as Potential Antiobesity Agents
por: Gooda Sahib, Najla, et al.
Publicado: (2012)

Lorcaserin: A novel antiobesity drug
por: Brashier, Dick B. S., et al.
Publicado: (2014)

Current Understanding of Antiobesity Property of Capsaicin
por: Narang, Nithida, et al.
Publicado: (2017)

Copper Ionophores as Novel Antiobesity Therapeutics
por: Meggyesy, Peter M., et al.
Publicado: (2020)

Structural determinants of dual incretin receptor agonism by tirzepatide
por: Sun, Bingfa, et al.
Publicado: (2022)

The Potential Utility of Tirzepatide for the Management of Polycystic Ovary Syndrome
por: Anala, Alekya Devi, et al.
Publicado: (2023)

Oral Semaglutide
por: Bui, Vinh, et al.
Publicado: (2018)

Safety of Semaglutide
por: Smits, Mark M., et al.
Publicado: (2021)

Bizarre T Waves: What Do They Mean?
por: Bracey, Alexander, et al.
Publicado: (2021)

Structures of active melanocortin-4 receptor–Gs-protein complexes with NDP-α-MSH and setmelanotide
por: Heyder, Nicolas A., et al.
Publicado: (2021)

Understanding the Patient Experience of Hunger and Improved Quality of Life with Setmelanotide Treatment in POMC and LEPR Deficiencies
por: Wabitsch, Martin, et al.
Publicado: (2022)

Beneficial Effects of Setmelanotide in a 5-Year-Old Boy With POMC Deficiency and on His Caregivers
por: Dubern, Beatrice, et al.
Publicado: (2023)

SAT656 Weight Reduction After 6 Months Of Setmelanotide Treatment In Patients With Hypothalamic Obesity
por: Roth, Christian L, et al.
Publicado: (2023)

Shifting paradigms: Reframing coverage of antiobesity medications for plan sponsors
por: Green, Libbi, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_tgn5kpgcg9rr6uf1qu12pup0ao